Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioblastoma × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Neoplasm Metastasis 3 Lung Neoplasms 3 Neoplasms 2 Hematologic Neoplasms 2 Breast Neoplasms 2 Thyroid Neoplasms 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Anaplastic 1 Glioblastoma 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Adenocarcinoma of Lung 1 ALK Gene Rearrangement Positive 1

Interventions

Temozolomide 244 Radiotherapy 112 Bevacizumab 94 Magnetic Resonance Spectroscopy 50 Radiation 43 pembrolizumab 29 Irinotecan 27 Lomustine 20 Surgical Procedures, Operative 18 Radiosurgery 18 Nivolumab 17 Carmustine 16 Specimen Handling 15 Erlotinib Hydrochloride 15 Aminolevulinic Acid 15 Radiotherapy, Intensity-Modulated 13 Drug Therapy 12 Chemotherapy, Adjuvant 12 Carboplatin 12 Blood Specimen Collection 12 O(6)-benzylguanine 11 Cyclophosphamide 11 sargramostim 10 Thalidomide 10 Filgrastim 9 Etoposide 9 poly ICLC 8 Sunitinib 8 Imatinib Mesylate 8 Everolimus 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03158389 2023-09-28

N²M²

University Hospital Heidelberg

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡